Literature DB >> 8162075

A disease locus for hereditary haemorrhagic telangiectasia maps to chromosome 9q33-34.

M T McDonald1, K A Papenberg, S Ghosh, A A Glatfelter, B B Biesecker, E A Helmbold, D S Markel, A Zolotor, W C McKinnon, J L Vanderstoep.   

Abstract

Hereditary haemorrhagic telangiectasia (HHT), or Osler-Weber-Rendu disease, is an autosomal dominant vascular dysplasia of unknown pathogenesis leading to 'widespread' dermal, mucosal and visceral telangiectases and recurrent haemorrhage. We have mapped the HHT gene, by linkage analysis, to markers on 9q33-34 in two large multi-generation families. Haplotype analysis and mapping of recombination breakpoints gives a 4 cM interval between D9S61 and D9S63 as the most likely location of the gene. The closest marker, D9S65, is estimated to be within 1 cM of the gene and shows a combined lod score of 11.41. Two potential candidate genes, COL5A1 and ZNF79, are also located within 9q33-34. These results provide a starting point for the eventual cloning of the HHT gene.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8162075     DOI: 10.1038/ng0294-197

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  31 in total

Review 1.  Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms.

Authors:  C L Shovlin; M Letarte
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1.

Authors:  A Bourdeau; U Cymerman; M E Paquet; W Meschino; W C McKinnon; A E Guttmacher; L Becker; M Letarte
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  Clinical heterogeneity in hereditary haemorrhagic telangiectasia: are pulmonary arteriovenous malformations more common in families linked to endoglin?

Authors:  J N Berg; A E Guttmacher; D A Marchuk; M E Porteous
Journal:  J Med Genet       Date:  1996-03       Impact factor: 6.318

4.  Genetic heterogeneity in hereditary haemorrhagic telangiectasia.

Authors:  M E Porteous; A Curtis; O Williams; D Marchuk; S S Bhattacharya; J Burn
Journal:  J Med Genet       Date:  1994-12       Impact factor: 6.318

5.  Intrahepatic porto-hepatic venous shunts in Rendu-Osler-Weber disease: imaging demonstration.

Authors:  Shunro Matsumoto; Hiromu Mori; Yasunari Yamada; Tomoko Hayashida; Yuzo Hori; Hiro Kiyosue
Journal:  Eur Radiol       Date:  2003-09-20       Impact factor: 5.315

6.  Hereditary hemorrhagic telangiectasia in Japanese patients.

Authors:  Masaki Komiyama; Tomoya Ishiguro; Osamu Yamada; Hiroko Morisaki; Takayuki Morisaki
Journal:  J Hum Genet       Date:  2013-11-07       Impact factor: 3.172

7.  Linkage of hereditary haemorrhagic telangiectasia to chromosome 9q34 and evidence for locus heterogeneity.

Authors:  P Heutink; T Haitjema; G J Breedveld; B Janssen; L A Sandkuijl; C J Bontekoe; C J Westerman; B A Oostra
Journal:  J Med Genet       Date:  1994-12       Impact factor: 6.318

8.  Genetic heterogeneity in hereditary haemorrhagic telangiectasia: possible correlation with clinical phenotype.

Authors:  K A McAllister; F Lennon; B Bowles-Biesecker; W C McKinnon; E A Helmbold; D S Markel; C E Jackson; A E Guttmacher; M A Pericak-Vance; D A Marchuk
Journal:  J Med Genet       Date:  1994-12       Impact factor: 6.318

9.  Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative.

Authors:  N Pece; S Vera; U Cymerman; R I White; J L Wrana; M Letarte
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

10.  Mutation analysis of "Endoglin" and "Activin receptor-like kinase" genes in German patients with hereditary hemorrhagic telangiectasia and the value of rapid genotyping using an allele-specific PCR-technique.

Authors:  Haneen Sadick; Johanna Hage; Ulrich Goessler; Jens Stern-Straeter; Frank Riedel; Karl Hoermann; Peter Bugert
Journal:  BMC Med Genet       Date:  2009-06-09       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.